Autopsy report · NCT04904562

Angiotensin II for Distributive Shock

“Enrollment Challenges”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 1 month before it started.
• Ran for about 2 years 1 month before it stopped.
• 2 participants enrolled.
• Results were posted on the registry 1 year 9 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Northwestern University

Sponsor type

University, hospital or other

Conditions

Distributive Shock

Interventions

Angiotensin II; Placebo

Participants

2

Sites

1

Countries

United States

Trials that died the same way

• A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
  “Major challenge for enrollment of participants.” (88% match in meaning)
• Early Childhood Obesity Among Rural Residents of West Texas
  “Enrollment issues” (86% match in meaning)
• Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
  “Enrollment challenges, study not feasible” (85% match in meaning)
• Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts
  “Difficulties of enrollment” (85% match in meaning)
• Tiotropium vs. Inhaled Corticosteroids in Children With Nonatopic Asthma Pilot Study (TioNAAP)
  “Difficult enrollment” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.